Based on data from the not yet fully reported results of the Keynote-811 study, the Commission for Human Medical Products (CHMP) of the European Medicines Agency (EMA) published a positive opinion for pembrolizumab plus trastuzumab and chemotherapy as first-line treatment for HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma expressing PD-L1 (CPS ≥ 1) on 20th of July 2023 (https://www.ema.europa.eu/en/medicines/human/summaries-opinion/keytruda-10). Here, ERBB2 is linked to adenocarcinoma.